20 research outputs found
L'art suisse à Zurich
"Une petite nationale" au Kunsthaus de Zurich. Hodler, Vautier, Blanchet, Vallet, etc
Area under the curve of immunosuppressants.
<p>Area under the curve of immunosuppressants.</p
Gd-IgA1, total IgA1 and IgA-IgG complexes in recurrent and non-recurrent patients at t0, t3 and t6.
<p>Gd-IgA1, total IgA1 and IgA-IgG complexes in recurrent and non-recurrent patients at t0, t3 and t6.</p
a, b, and c. Changes of galactose-deficient IgA1, total IgA1 and IgA-IgG complexes over time under influence of changing degrees of immunosuppression with tacrolimus, mycophenolate mofetil (MMF) and prednisone.
<p>Boxes represent the median 50% of patients, lower and upper box ends are the 25th and 75th percentiles, and the middle bar represents the median. Whiskers link the lower/ upper box ends with the 5th and the 95th percentile. Outliers are represented by a closed circle.</p
a, b, c Area under the curve of tacrolimus, MMF and prednisone over the study period from t<sub>0</sub> to t<sub>6</sub>.
<p>a, b, c Area under the curve of tacrolimus, MMF and prednisone over the study period from t<sub>0</sub> to t<sub>6</sub>.</p
ROC analysis shows thresholds of protection from concurrent CMV replication for the different CMV antigens tested
AUC, Area under the curve; p-value by Fisher exact test; PPV, positive predictive value; NPV, negative predictive value.<p><b>Copyright information:</b></p><p>Taken from "Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients"</p><p>http://www.translational-medicine.com/content/6/1/29</p><p>Journal of Translational Medicine 2008;6():29-29.</p><p>Published online 9 Jun 2008</p><p>PMCID:PMC2432058.</p><p></p
Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients-1
Hout concurrent CMV replication. Note: The median was below the analytical cut-off of 0.01% in for the pp65-induced CD 4+ and CD8+ responses in patients with concurrent CMV replication.<p><b>Copyright information:</b></p><p>Taken from "Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients"</p><p>http://www.translational-medicine.com/content/6/1/29</p><p>Journal of Translational Medicine 2008;6():29-29.</p><p>Published online 9 Jun 2008</p><p>PMCID:PMC2432058.</p><p></p
Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients-0
Ve D(+)R(-) KT patients. Black bars indicate median, whiskers indicate interquartile range. P-values were calculated using Mann-Whitney U test. Note: The median was below the analytical cut-off of 0.01% in the CMV-seronegative D(+)R(-) KT patients.<p><b>Copyright information:</b></p><p>Taken from "Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients"</p><p>http://www.translational-medicine.com/content/6/1/29</p><p>Journal of Translational Medicine 2008;6():29-29.</p><p>Published online 9 Jun 2008</p><p>PMCID:PMC2432058.</p><p></p
Image_4_The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation – Data from the Swiss transplant cohort study.jpeg
BackgroundPre-transplant donor specific antibodies (DSA), directed at non-self human leukocyte antigen (HLA) protein variants present in the donor organ, have been associated with worse outcomes in kidney transplantation. The impact of the mean fluorescence intensity (MFI) and the target HLA antigen of the detected DSA has, however, not been conclusively studied in a large cohort with a complete virtual cross-match (vXM).MethodsWe investigated the effect of pre-transplant DSA on the risk of antibody-mediated rejection (ABMR), graft loss, and the rate of eGFR decline in 411 DSA positive transplants and 1804 DSA negative controls.ResultsPre-transplant DSA were associated with a significantly increased risk of ABMR, graft loss, and accelerated eGFR decline. DSA directed at Class I and Class II HLA antigens were strongly associated with increased risk of ABMR, but only DSA directed at Class II associated with graft loss. DSA MFI markedly affected outcome, and Class II DSA were associated with ABMR already at 500-1000 MFI, whereas Class I DSA did not affect outcome at similar low MFI values. Furthermore, isolated DSA against HLA-DP carried comparable risks for ABMR, accelerated eGFR decline, and graft loss as DSA against HLA-DR.ConclusionOur results have important implications for the construction and optimization of vXM algorithms used within organ allocation systems. Our data suggest that both the HLA antigen target of the detected DSA as well as the cumulative MFI should be considered and that different MFI cut-offs could be considered for Class I and Class II directed DSA.</p